

Jay Berzofsky, et al.
Application No. 09/508,552
Page 4

PATENT

Kindly replace the paragraph at page 48, lines 3-7, with the following paragraph:

~~One possible difference between CTL induced by mucosal versus systemic immunization is that the CTL resulting from the SC immunization do not have homing receptors for the GI mucosa, as evidenced by the fact that they are not detected in the lamina propria or Peyer's patches.~~

IN THE CLAIMS:

Kindly replace claims 6, 27, 48 and 66 with the following substitute claims. An Appendix showing all changes to these claims is attached to this amendment as required by 37 CFR §1.121(e).

1 6. (Amended) The method of claim 5, wherein the cytokine is contacted with a
2 mucosal surface of the subject.

1 27. (Amended) The method of claim 26, wherein the cytokine is contacted with
2 a mucosal surface of the subject.

1 48. (Amended) The immunogenic composition of claim 46, further comprising
2 a base, carrier, or absorption-promoting agent adapted for intrarectal delivery.

1 66. (Amended) The immunogenic composition of claim 64, wherein the protein
2 or peptide is an HIV V3 loop or T cell-binding peptide fragment thereof.

REMARKS

The Restriction Requirement dated July 5, 2001, set forth the following groups of claims:

I. Claims 1-16, 21-37, and 42-69, drawn to a composition and method using HIV-1 antigens classified in Class 424, subclass 85.6,